Abstract
With the beginning of the 21st century, a new and exciting era for cancer therapy has begun with the appearance of molecular targeted drugs. Numerous drugs for chemotherapy have been discovered following careful screening of natural and synthetic components. After screening, candidate chemotherapy drugs are examined to determine if they have sufficiently cytotoxic to function as an anti-tumor therapeutic. However, the development of molecular targeted drugs is based on more logical methodologies. First, the target is determined then a search is conducted for molecules able to inhibit the target molecule. Some molecular targeting drugs, such as Glivec (Imatinib, STI571), have shown amazing effects when compared to currently used chemotherapy drugs, whereas few others have completely failed to inhibit tumor development in clinical trials. Thus, an efficient method for finding effective molecular targeted drugs is needed. An important question is whether the target molecule is responsible for tumor growth or metastasis. In addition, the clinical administration schedule must be suitable for the component used. The drugs will not be completely successful in clinical trials if any of the key points are overlooked. Translational studies are necessary for a complete evaluation of molecular targeted drugs and, based on the results observed in clinical applications, the testers must return to their basic laboratory if necessary and improve the drugs for more advanced therapy. In this review we discuss on the current and future status of molecular target drugs.
Keywords: Cancer, molecular targeted therapy, antibody, small molecule, personalized medicine, proof of principle, translational research, review
Current Cancer Drug Targets
Title: Current Status and Future of Target-Based Therapeutics
Volume: 7 Issue: 3
Author(s): Ryoko Suzuki, Parijatha Rao and Shiro Sasaguri
Affiliation:
Keywords: Cancer, molecular targeted therapy, antibody, small molecule, personalized medicine, proof of principle, translational research, review
Abstract: With the beginning of the 21st century, a new and exciting era for cancer therapy has begun with the appearance of molecular targeted drugs. Numerous drugs for chemotherapy have been discovered following careful screening of natural and synthetic components. After screening, candidate chemotherapy drugs are examined to determine if they have sufficiently cytotoxic to function as an anti-tumor therapeutic. However, the development of molecular targeted drugs is based on more logical methodologies. First, the target is determined then a search is conducted for molecules able to inhibit the target molecule. Some molecular targeting drugs, such as Glivec (Imatinib, STI571), have shown amazing effects when compared to currently used chemotherapy drugs, whereas few others have completely failed to inhibit tumor development in clinical trials. Thus, an efficient method for finding effective molecular targeted drugs is needed. An important question is whether the target molecule is responsible for tumor growth or metastasis. In addition, the clinical administration schedule must be suitable for the component used. The drugs will not be completely successful in clinical trials if any of the key points are overlooked. Translational studies are necessary for a complete evaluation of molecular targeted drugs and, based on the results observed in clinical applications, the testers must return to their basic laboratory if necessary and improve the drugs for more advanced therapy. In this review we discuss on the current and future status of molecular target drugs.
Export Options
About this article
Cite this article as:
Suzuki Ryoko, Rao Parijatha and Sasaguri Shiro, Current Status and Future of Target-Based Therapeutics, Current Cancer Drug Targets 2007; 7 (3) . https://dx.doi.org/10.2174/156800907780618275
DOI https://dx.doi.org/10.2174/156800907780618275 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Anticancer Activity of Phthalimido and Naphthalimido Substituted Dihydropyrimidone Conjugates
Letters in Drug Design & Discovery Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy
Current Cancer Drug Targets Natural Antibodies: Protecting Role of IgM in Glioblastoma and Brain Tumours
Current Pharmaceutical Design Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Nuclear Hormone Receptors and Female Reproduction
Current Molecular Medicine Synthesis of Cis-Fused Pyran Indolocarbazole Derivatives that Inhibit FLT3 Kinase and the DNA Damage Kinase, Checkpoint Kinase 1
Anti-Cancer Agents in Medicinal Chemistry Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Glutaminase Isoenzymes as Key Regulators in Metabolic and Oxidative Stress Against Cancer
Current Molecular Medicine A Role for Milk Proteins and their Peptides in Cancer Prevention
Current Pharmaceutical Design In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Overview of Tumor-Associated Antigens (TAAs) as Potential Therapeutic Targets for Prostate Cancer Therapy
Current Cancer Therapy Reviews Nuclear Receptor SHP as a Potential Therapeutic Target for Liver Cancer
Current Cancer Therapy Reviews The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Potential Interactions between miRNAs and Hypoxia: A New Layer in Cancer Hypoxia
Anti-Cancer Agents in Medicinal Chemistry Cardiovascular Biology of Interleukin-6
Current Pharmaceutical Design Receptor Tyrosine Kinases as Therapeutic Targets in Malignant Glioma
Reviews on Recent Clinical Trials ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Current Pharmaceutical Design Palifermin in theManagement of Mucositis in Hematological Malignancies: Current Evidences and Future Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry Germ Cell Apoptosis: Relevance to Infertility and Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Anticancer Properties of Dietary Polyphenols and its Relation with Apoptosis
Current Pharmaceutical Design